 prospective randomized evaluation intensive-course doxorubicin surgical adjuvant chemotherapy resected gastric cancer study combined postoperative adjuvant chemotherapy patients curative resection primary gastric adenocarcinoma twenty-five eligible evaluable patients extent surgical resection location primary tumor stomach node status receive cycles chemotherapy median time patient entry years Results significant difference time survival rate observation arm adjuvant therapy arm data improvement survival rate patients chemotherapy value drug-related fatalities due results substantive benefit chemotherapy regimen postoperative adjuvant treatment resected gastric cancer